Tolera Ambisa Lamesa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tolera Ambisa Lamesa has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Gebeyaw Arega Berihun
Department of Medical Laboratory, Institute of Health Science, Jimma University, Jimma, South West, Ethiopia
2 shared publicationsAklilu Getachew Mamo
School of Medical Laboratory Science, Faulty of Health Science, Institute of Health, Jimma University, Jimma, Ethiopia
1 shared publication- Aklilu Getachew Mamo
School of Medical Laboratory Science Faculty of Health Sciences Institute of Health Jimma University Jimma Oromia Regional State Ethiopia ju.edu.et
1 shared publication Bedasa Addisu
Department of Medical Laboratory Science, Debre Berhan University, Debre Berhan, Ethiopia
1 shared publicationBelay Merkeb Zewude
Department of Medical Laboratory Science, College of Health Science, Salale University, Fitche, Ethiopia
1 shared publication- Dereje Abebe Regassa
Wolkite Univ, Dept Med Lab Sci, POB 07, Wolkite 11330, Ethiopia
1 shared publication
Latest Publications
- Open Access
- 24 June 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (6) , e0325775
Hyperuricemia and associated factors among adult cardiovascular disease patients at Salale University Comprehensive Specialized Hospital, Fitche, Central Ethiopia
Background: Despite evidence suggesting that hyperuricemia (serum uric acid >7.0 mg/dL in males and >6.0 mg/dL in females) contributes to adverse outcomes like mortality and hospitalization in patients with cardiovascular disease (CVD), a comprehensive understanding of its magnitude is still lacking, underscoring the need for further investigation. There is no previously published study about hyperuricemia in cardiovascular disease in Ethiopia. Therefore, this study aims to investigate the prevalence of hyperuricemia and its associated factors among adult patients with cardiovascular diseases at Salale University Compressive Specialized Hospital Located in Fitche, Ethiopia (115 km north of Addis Ababa),from October 1, 2023, to January 28, 2024. Materials and methods: A hospital-based cross-sectional study was conducted on 298 participants with different types of cardiovascular disease. The participants were selected using a consecutive sampling technique. Socio-demographic factors were collected using interviewer-administered questionnaires, while overnight blood samples were collected and biochemical tests were analyzed using the COBAS c 311 automated clinical chemistry analyzer. Descriptive statistics and logistic regression analyses were performed. A variable that had a p-value of ≤ 0.05 with a 95% confidence interval was considered statistically significant. Result: The prevalence of hyperuricemia among adult cardiovascular disease patients was 41.3% CI [35.6–47.1]. The highest prevalence of hyperuricemia was found among cardiovascular disease patients with congestive heart failure (48.0%) and hypertensive heart disease (41.2%). Factors such as physical activity (AOR: 4.1; 95% CI: 1.5–10.7, P = 0.004), dyslipidemia (AOR: 2.7; 95% CI: 1.2–6.0, P = 0.01) and chronic kidney disease (AOR: 3.1; 95% CI: 1.5–6.1, P = 0.001) were found to be associated with hyperuricemia among individuals with cardiovascular disease. Conclusion: The study indicated a high prevalence of hyperuricemia among participants with cardiovascular disease. Physical activity, dyslipidemia, and chronic kidney disease were recognized as significant associated factors of hyperuricemia among cardiovascular disease. Therefore, early diagnosis of hyperuricemia and its management is essential to control complications and extend the life expectancy of individuals with cardiovascular disease.
- 24 June 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (6) , e0325775
Open AccessHyperuricemia and associated factors among adult cardiovascular disease patients at Salale University Comprehensive Specialized Hospital, Fitche, Central Ethiopia
Background: Despite evidence suggesting that hyperuricemia (serum uric acid >7.0 mg/dL in males and >6.0 mg/dL in females) contributes to adverse outcomes like mortality and hospitalization in patients with cardiovascular disease (CVD), a comprehensive understanding of its magnitude is still lacking, underscoring the need for further investigation. There is no previously published study about hyperuricemia in cardiovascular disease in Ethiopia. Therefore, this study aims to investigate the prevalence of hyperuricemia and its associated factors among adult patients with cardiovascular diseases at Salale University Compressive Specialized Hospital Located in Fitche, Ethiopia (115 km north of Addis Ababa),from October 1, 2023, to January 28, 2024. Materials and methods: A hospital-based cross-sectional study was conducted on 298 participants with different types of cardiovascular disease. The participants were selected using a consecutive sampling technique. Socio-demographic factors were collected using interviewer-administered questionnaires, while overnight blood samples were collected and biochemical tests were analyzed using the COBAS c 311 automated clinical chemistry analyzer. Descriptive statistics and logistic regression analyses were performed. A variable that had a p-value of ≤ 0.05 with a 95% confidence interval was considered statistically significant. Result: The prevalence of hyperuricemia among adult cardiovascular disease patients was 41.3% CI [35.6–47.1]. The highest prevalence of hyperuricemia was found among cardiovascular disease patients with congestive heart failure (48.0%) and hypertensive heart disease (41.2%). Factors such as physical activity (AOR: 4.1; 95% CI: 1.5–10.7, P = 0.004), dyslipidemia (AOR: 2.7; 95% CI: 1.2–6.0, P = 0.01) and chronic kidney disease (AOR: 3.1; 95% CI: 1.5–6.1, P = 0.001) were found to be associated with hyperuricemia among individuals with cardiovascular disease. Conclusion: The study indicated a high prevalence of hyperuricemia among participants with cardiovascular disease. Physical activity, dyslipidemia, and chronic kidney disease were recognized as significant associated factors of hyperuricemia among cardiovascular disease. Therefore, early diagnosis of hyperuricemia and its management is essential to control complications and extend the life expectancy of individuals with cardiovascular disease.
- Open Access
- 8 March 2025
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 112 (2) , 116789
Co-infection of intestinal protozoa and intestinal parasites with Helicobacter pylori among HIV AIDS patients at Jimma Medical Center, Ethiopia
- 8 March 2025
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 112 (2) , 116789
Open AccessCo-infection of intestinal protozoa and intestinal parasites with Helicobacter pylori among HIV AIDS patients at Jimma Medical Center, Ethiopia
- Open Access
- 1 April 2024
- Published by Taylor & Francis in HIV/AIDS - Research and Palliative Care
- Vol. ume 16, 123-132
Biological Depiction of Lipodystrophy and Its Associated Challenges Among HIV AIDS Patients: Literature Review
Lipodystrophy syndrome is a medical condition characterized by the absence of adipose tissue without any underlying starvation or macromolecule breakdown. In HIV AIDS patients, the use of highly active antiretroviral therapy (HAART) can lead to an acquired form of lipodystrophy, with a prevalence ranging from 10% to 83% among HIV AIDS patients. It was aimed to review the current understanding of biological depiction and challenges related to lipodystrophy in AIDS patients. Relevant articles published in the English language were searched in PubMed, Google Scholar, and Google. Keywords used for the search were: lipodystrophy, lipodystrophy and HIV, ART and lipodystrophy, HIV treatment, metabolic syndrome and HIV. Articles with full abstract information were read for those that met the objective criteria of the review, then full text of the articles was accessed and used. It was revealed by the literature that patients who developed lipodystrophy are characterized by insulin abnormality, obesity, diabetes mellitus, dyslipidemia, fatty liver disease, and ovarian dysfunction. Anthropometric measurements have been known to change significantly with lipodystrophy. HIV patients suffering from hepatitis C virus, hepatitis B virus, who take a protease inhibitor, are changing treatment or duration of treatment, and are women are the common risk factors for lipodystrophy. The metabolic syndrome seen in HIV patients associated with lipodystrophy can further be complicated to different adverse health effects and can result in increased morbidity and mortality rate if not treated. Existing studies have successfully identified several challenges faced by HIV AIDS patients due to lipodystrophy, including low self-esteem, compromised quality of life, and poor treatment adherence. However, it is crucial to acknowledge that there may be numerous other challenges that have yet to be discovered, emphasizing the need for further studies. It is recommended that managing dyslipidemia, treating diabetes mellitus, modifying lifestyle, and improving the anthropometric measurements have crucial roles to halt further complications associated with lipodystrophy.
- 1 April 2024
- Published by Taylor & Francis in HIV/AIDS - Research and Palliative Care
- Vol. ume 16, 123-132
Open AccessBiological Depiction of Lipodystrophy and Its Associated Challenges Among HIV AIDS Patients: Literature Review
Lipodystrophy syndrome is a medical condition characterized by the absence of adipose tissue without any underlying starvation or macromolecule breakdown. In HIV AIDS patients, the use of highly active antiretroviral therapy (HAART) can lead to an acquired form of lipodystrophy, with a prevalence ranging from 10% to 83% among HIV AIDS patients. It was aimed to review the current understanding of biological depiction and challenges related to lipodystrophy in AIDS patients. Relevant articles published in the English language were searched in PubMed, Google Scholar, and Google. Keywords used for the search were: lipodystrophy, lipodystrophy and HIV, ART and lipodystrophy, HIV treatment, metabolic syndrome and HIV. Articles with full abstract information were read for those that met the objective criteria of the review, then full text of the articles was accessed and used. It was revealed by the literature that patients who developed lipodystrophy are characterized by insulin abnormality, obesity, diabetes mellitus, dyslipidemia, fatty liver disease, and ovarian dysfunction. Anthropometric measurements have been known to change significantly with lipodystrophy. HIV patients suffering from hepatitis C virus, hepatitis B virus, who take a protease inhibitor, are changing treatment or duration of treatment, and are women are the common risk factors for lipodystrophy. The metabolic syndrome seen in HIV patients associated with lipodystrophy can further be complicated to different adverse health effects and can result in increased morbidity and mortality rate if not treated. Existing studies have successfully identified several challenges faced by HIV AIDS patients due to lipodystrophy, including low self-esteem, compromised quality of life, and poor treatment adherence. However, it is crucial to acknowledge that there may be numerous other challenges that have yet to be discovered, emphasizing the need for further studies. It is recommended that managing dyslipidemia, treating diabetes mellitus, modifying lifestyle, and improving the anthropometric measurements have crucial roles to halt further complications associated with lipodystrophy.
- Open Access
- 1 February 2024
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 15, 87-99
Magnitude, Associated Factors and Morphological Types of Anemia Among Hospitalized 6–59 Months Age Children at Jimma Medical Center, Southwest Ethiopia – A Hospital-Based Cross-Sectional Study
Background: Anemia is among the major public health problems that cause significant morbidity and mortality among children around the world. Anemia in children of age 6 months to 5 years is a major health problem in most developing world countries with estimated prevalence of about 43%. Objective: To determine the magnitude, associated factors and morphological types of anemia among hospitalized 6– 59 months age children from June 15 to October 15, 2022 at Jimma Medical Center, southwest Ethiopia. Methodology: Hospital-based cross- sectional study design was conducted from June 15 to October 15, 2022 at Jimma Medical Center, involving 383 hospitalized children aged 6– 59 months by employing convenient sampling technique. Data of sociodemographic characteristics and other associated factors of the study individuals waere collected using a pre-structured questionnaire. Clinical data were collected by physical examination and from history of client by medical interns and nurses. Then 3 mL venous blood was collected and analyzed for complete blood count. Data were coded, cleared and entered into EpiData version 4.6 and exported to SPSS version 25 for analysis. Bivariable and multivariable binary logistic regression was used to identify associated factors. Results: The overall prevalence of anemia among hospitalized 6– 59 months age children was 57.2%; out of them 30.82% were moderate. In the present study children with malaria infection, AOR = 1.15 (95% CI: 0.017, 0.781), Cchildren with severe malnutrition, AOR = 2.046 (95% CI: 0.306, 1.366), and children with low family income, AOR = 2.6 (95% CI 0.475, 0.894) were independent variables associated with anemia. Conclusion and Recommendation: Anemia among study participants is found to be a severe public health problem. Based on this finding, more intervention is needed with health education on nutrition and child feeding.
- 1 February 2024
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 15, 87-99
Open AccessMagnitude, Associated Factors and Morphological Types of Anemia Among Hospitalized 6–59 Months Age Children at Jimma Medical Center, Southwest Ethiopia – A Hospital-Based Cross-Sectional Study
Background: Anemia is among the major public health problems that cause significant morbidity and mortality among children around the world. Anemia in children of age 6 months to 5 years is a major health problem in most developing world countries with estimated prevalence of about 43%. Objective: To determine the magnitude, associated factors and morphological types of anemia among hospitalized 6– 59 months age children from June 15 to October 15, 2022 at Jimma Medical Center, southwest Ethiopia. Methodology: Hospital-based cross- sectional study design was conducted from June 15 to October 15, 2022 at Jimma Medical Center, involving 383 hospitalized children aged 6– 59 months by employing convenient sampling technique. Data of sociodemographic characteristics and other associated factors of the study individuals waere collected using a pre-structured questionnaire. Clinical data were collected by physical examination and from history of client by medical interns and nurses. Then 3 mL venous blood was collected and analyzed for complete blood count. Data were coded, cleared and entered into EpiData version 4.6 and exported to SPSS version 25 for analysis. Bivariable and multivariable binary logistic regression was used to identify associated factors. Results: The overall prevalence of anemia among hospitalized 6– 59 months age children was 57.2%; out of them 30.82% were moderate. In the present study children with malaria infection, AOR = 1.15 (95% CI: 0.017, 0.781), Cchildren with severe malnutrition, AOR = 2.046 (95% CI: 0.306, 1.366), and children with low family income, AOR = 2.6 (95% CI 0.475, 0.894) were independent variables associated with anemia. Conclusion and Recommendation: Anemia among study participants is found to be a severe public health problem. Based on this finding, more intervention is needed with health education on nutrition and child feeding.
- Open Access
- 1 September 2023
- Published by Taylor & Francis in HIV/AIDS - Research and Palliative Care
- Vol. ume 15, 537-547
Dyslipidemia and Nutritional Status of HIV-Infected Children and Adolescents on Antiretroviral Treatment at the Comprehensive Chronic Care and Training Center of Jimma Medical Center
Background: Highly active antiretroviral treatment is beneficial to suppress human immune virus replication in infected individuals. However, dyslipidemia and other metabolic abnormalities have emerged due to antiretroviral treatment. The prevalence of dyslipidemia in children and adolescents on antiretroviral treatment varies from 20% to 70%. The lack of data on children and adolescents in Ethiopia was the rationale for conducting this study. We aimed to determine prevalence of dyslipidemia and nutritional status in children and adolescents on follow-up at Jimma medical center. Materials and Methods: A hospital-based cross-sectional study was conducted with 150 children and adolescents on follow-up at Jimma medical center. A systematic sampling technique was employed. An interview was carried out to collect socioeconomic and demographic data and a review of medical records was carried out to collect patients’ clinical data. Anthropometric data were computed using the CDC growth chart. About 3– 5mL of fasting blood was collected to measure lipid profile. Multivariable logistic regression was performed to find the association between risk factors and lipid profile. Results: The overall prevalence of dyslipidemia in this study was 72%. About 72% and 21.3% of study subjects had low high-density lipoprotein and high triglyceride, respectively. Significant associations were observed between BMI for age ≤ 5% (AOR: 2.02, 95% CI: 1.14– 3.66; P=0.015) and low high-density lipoprotein; greater than 150 months on treatment (AOR: 1.02, 95% CI: 1.00– 1.03; P=0.01) and high triglyceride; and BMI for age ≤ 5% (AOR: 1.86, 95% CI: 1.03– 1.37; P=0.04) and high triglyceride. Conclusion: BMI for age < 5%, treatment duration of greater than 150 months, and parents’ educational level were significantly associated with dyslipidemia, so it is recommended that monitoring of those variables will help to reduce dyslipidemia and its complications in children and adolescents receiving treatment.
- 1 September 2023
- Published by Taylor & Francis in HIV/AIDS - Research and Palliative Care
- Vol. ume 15, 537-547
Open AccessDyslipidemia and Nutritional Status of HIV-Infected Children and Adolescents on Antiretroviral Treatment at the Comprehensive Chronic Care and Training Center of Jimma Medical Center
Background: Highly active antiretroviral treatment is beneficial to suppress human immune virus replication in infected individuals. However, dyslipidemia and other metabolic abnormalities have emerged due to antiretroviral treatment. The prevalence of dyslipidemia in children and adolescents on antiretroviral treatment varies from 20% to 70%. The lack of data on children and adolescents in Ethiopia was the rationale for conducting this study. We aimed to determine prevalence of dyslipidemia and nutritional status in children and adolescents on follow-up at Jimma medical center. Materials and Methods: A hospital-based cross-sectional study was conducted with 150 children and adolescents on follow-up at Jimma medical center. A systematic sampling technique was employed. An interview was carried out to collect socioeconomic and demographic data and a review of medical records was carried out to collect patients’ clinical data. Anthropometric data were computed using the CDC growth chart. About 3– 5mL of fasting blood was collected to measure lipid profile. Multivariable logistic regression was performed to find the association between risk factors and lipid profile. Results: The overall prevalence of dyslipidemia in this study was 72%. About 72% and 21.3% of study subjects had low high-density lipoprotein and high triglyceride, respectively. Significant associations were observed between BMI for age ≤ 5% (AOR: 2.02, 95% CI: 1.14– 3.66; P=0.015) and low high-density lipoprotein; greater than 150 months on treatment (AOR: 1.02, 95% CI: 1.00– 1.03; P=0.01) and high triglyceride; and BMI for age ≤ 5% (AOR: 1.86, 95% CI: 1.03– 1.37; P=0.04) and high triglyceride. Conclusion: BMI for age < 5%, treatment duration of greater than 150 months, and parents’ educational level were significantly associated with dyslipidemia, so it is recommended that monitoring of those variables will help to reduce dyslipidemia and its complications in children and adolescents receiving treatment.